Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo.
| dc.contributor.author | Davidson, Jonathan | |
| dc.contributor.author | Stein, Dan J | |
| dc.contributor.author | Rothbaum, Barbara O | |
| dc.contributor.author | Pedersen, Ron | |
| dc.contributor.author | Szumski, Annette | |
| dc.contributor.author | Baldwin, David S | |
| dc.date.accessioned | 2022-10-01T18:04:07Z | |
| dc.date.available | 2022-10-01T18:04:07Z | |
| dc.date.issued | 2012-06 | |
| dc.date.updated | 2022-10-01T18:04:06Z | |
| dc.description.abstract | This post-hoc analysis evaluated resilience as a predictor of treatment response in patients with posttraumatic stress disorder (PTSD). Data were pooled from two randomized, double-blind studies conducted with adult outpatients treated with flexible doses of venlafaxine extended release (ER) 37.5 to 300 mg/day or placebo. The 17-item Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS-SX(17)) was the primary outcome measure. Baseline Connor-Davidson Resilience Scale (CD-RISC) scores for the 25-, 10-, and 2-item versions were used to predict changes in PTSD symptom severity at week 12 and symptomatic remission (CAPS-SX(17) ≤ 20). Analyses were conducted for the overall population and separately for the individual treatment groups. In total, pretreatment resilience predicted a positive treatment response. For the overall population, all versions of the CD-RISC predicted CAPS-SX(17) change scores and remission after controlling for variables such as treatment group and baseline symptom severity. For venlafaxine ER-treated patients, all versions of the CD-RISC were predictive of remission, but only the 10-item version was predictive of CAPS-SX(17) change score. Our results suggest that higher pretreatment resilience is generally associated with a positive treatment response. Future research may be warranted to explore the relationship between response to active treatment and the spectrum of resiliency. | |
| dc.identifier | 0269881111413821 | |
| dc.identifier.issn | 0269-8811 | |
| dc.identifier.issn | 1461-7285 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | SAGE Publications | |
| dc.relation.ispartof | Journal of psychopharmacology (Oxford, England) | |
| dc.relation.isversionof | 10.1177/0269881111413821 | |
| dc.subject | Humans | |
| dc.subject | Cyclohexanols | |
| dc.subject | Delayed-Action Preparations | |
| dc.subject | Treatment Outcome | |
| dc.subject | Double-Blind Method | |
| dc.subject | Stress Disorders, Post-Traumatic | |
| dc.subject | Psychiatric Status Rating Scales | |
| dc.subject | Female | |
| dc.subject | Male | |
| dc.subject | Resilience, Psychological | |
| dc.subject | Venlafaxine Hydrochloride | |
| dc.title | Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. | |
| dc.type | Journal article | |
| pubs.begin-page | 778 | |
| pubs.end-page | 783 | |
| pubs.issue | 6 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychology | |
| pubs.publication-status | Published | |
| pubs.volume | 26 |
Files
Original bundle
- Name:
- JPsychopharmacol - Resil as predictor June 2012.pdf
- Size:
- 217.52 KB
- Format:
- Adobe Portable Document Format